Group 1 - Nanjing Yuanmai Cell Biotechnology Co., Ltd. has successfully received joint investment from the Nanjing University Technology Achievement Transformation Angel Fund and the Future Industry Angel Fund, marking the official launch of the Nanjing University Technology Achievement Transformation Angel Fund established in March this year [1] - Yuanmai Cell, founded in September 2022, focuses on the research and development of cell immunotherapy drugs, leveraging four core technology platforms: CAR-T module design, sequence screening, efficient gene delivery, and iPSC differentiation [1] - The founder, Professor Shen Pingping, is recognized as a leading authority in macrophage research and has received multiple funding supports from national and provincial programs, enhancing the company's research capabilities [1] Group 2 - The investment reflects the critical role of government-guided funds in accelerating the transformation of university scientific achievements into productive forces, thereby enhancing Nanjing's influence in the gene and cell therapy industry [2] - The Nanjing University Technology Achievement Transformation Angel Fund has a total scale of 500 million yuan, marking it as the first university technology achievement transformation fund in Jiangsu Province's strategic emerging industry special fund [2] - The fund aims to address the "last mile" challenge in transforming university scientific achievements into tangible productivity, with a focus on supporting projects in the biomedical and information communication sectors [3]